Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atabecestat PK interaction with CYP3A4 inhibitors
NCT02197884Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of atabecestat in Alzheimer's disease (AD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 9, Time to Reach Maximum Concentration at Day 9 and 6 more. Started Jul 2014; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02197884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197884.